Vero Biotech: Secures $50M in Funding

  • Vero Biotech LLC, an Atlanta, Georgia-based biotechnology company, closed a senior secured term loan of $50m
  • Runway Growth Capital provided the financing
  • Vero Biotech (formerly known as GeNO LLC), a biotechnology company focused on the design, development, and commercialization of next-generation products
  • The company also developed the GENOSYL® Delivery System (GENOSYL DS), a inhaled nitric oxide delivery system approved by the U.S. Food and Drug Administration (FDA)
  • The GENOSYL DS transforms the delivery and use of nitric oxide, a vasodilator proven to play a critical role in the care of patients with adult respiratory distress syndrome
  • The GENOSYL® Delivery System authorized by the U.S. FDA for expanded emergency use access for patients with cardiopulmonary complications
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Talos and Nasdaq Strengthen On-Chain and Off-Chain Collateral Workflow

New partnership enhances digital asset handling and collateral management.Highlights: Talos and Nasdaq collaborate to streamline collateral workflows.Partnership aims...

FCA Restricts Use of Sensitive Data in AI Trial with Palantir

Regulatory concerns arise over data handling protocols in AI trials.Highlights: FCA criticized for using sensitive data in AI...

Bank of Ireland Strengthens AI Readiness for Staff Training

New initiatives prepare employees for an AI-driven banking landscape.Highlights: Bank of Ireland launches AI training initiatives for staff.Employees...

MAS Develops AI Risk Management Toolkit to Strengthen Financial Sector

New toolkit aims to enhance risk management within Singapore's finance industry.Highlights: MAS launches an AI Risk Management Toolkit...